Hexarelin and Reproductive Biology Research: GH Secretagogue Peptide, Gonadal Axis Modulation and Fertility Mechanisms UK 2026

This article is intended for researchers and laboratory professionals. All peptides discussed are for research use only (RUO) and are not approved for human administration, therapeutic use, or clinical application. PeptidesLab UK supplies research-grade Hexarelin for in vitro and in vivo laboratory investigations only.

Hexarelin Biology: Ghrelin Receptor Agonism Beyond Growth Hormone

Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide GH secretagogue developed as a potent agonist of the growth hormone secretagogue receptor 1a (GHSR-1a, also termed the ghrelin receptor). While hexarelin was originally characterised and extensively investigated for its GH-releasing properties — stimulating robust pulsatile GH release through a mechanism distinct from GHRH — subsequent research has uncovered its interaction with CD36 (a scavenger receptor expressed in cardiac tissue and reproductive organs), GHSR-1b (truncated splice variant), and potentially additional undescribed receptors, creating a pharmacological profile richer than simple GH-axis stimulation. For reproductive biology research, hexarelin’s significance derives from the dense GHSR-1a expression in gonadal tissues, the established role of ghrelin/GHSR signalling in HPG axis modulation, and the intersection between GH/IGF-1 and sex steroid biology.

GHSR-1a expression in reproductive tissues is well-characterised: rat and human pituitary gonadotrophs express GHSR-1a alongside GnRH-R; ovarian granulosa and theca cells express GHSR-1a mRNA and protein (RT-PCR, immunofluorescence); Leydig cells of the testis express GHSR-1a (relevant to testosterone regulation); and uterine endometrium and placenta express GHSR-1a during specific reproductive stages. This tissue expression pattern suggests direct gonadal effects of hexarelin independent of pituitary GH release.

HPG Axis Modulation: LH, FSH, and GnRH Pulse Interaction

Hexarelin and ghrelin both modulate the hypothalamic-pituitary-gonadal (HPG) axis, primarily through effects on GnRH pulse frequency and amplitude at the hypothalamic level, and through direct modulation of pituitary gonadotroph sensitivity to GnRH. Research using hypothalamic slice preparations and GT1-7 immortalised GnRH neurons demonstrates that GHSR-1a activation suppresses GnRH pulse frequency — a mechanism mediated through neuropeptide Y (NPY) co-neurons and via NPY Y1 receptor-coupled inhibition of GnRH neuron firing frequency (electrophysiology, patch-clamp, loose seal configuration). This ghrelin/hexarelin-NPY-GnRH signalling axis provides mechanistic context for the hypogonadism associated with chronic undernutrition and energy deficit states where ghrelin is elevated.

In vivo LH pulse profiling is the gold-standard HPG axis readout: serial blood sampling via jugular or tail vein cannula every 6 minutes for 3-4 hours, with ultra-sensitive LH ELISA (Steyn protocol, Shlomo Melmed laboratory methodology, detection limit ~0.016 IU/L). Hexarelin challenge (100-500 μg/kg i.v. or i.p.) and vehicle comparison in intact male/female rats or mice allow quantification of LH pulse frequency (pulses/3h), pulse amplitude (IU/L), inter-pulse interval (minutes), and mean LH concentration. GnRH antagonist (acyline, 330 μg/kg s.c.) or GnRH receptor KO models confirm pituitary-dependence versus direct hypothalamic effects. Kisspeptin-10 (10 nmol i.c.v.) serves as a positive control for LH surge induction, confirming HPG axis responsiveness in the model.

Leydig Cell Research: GHSR-1a and Testosterone Biosynthesis

The testicular Leydig cell represents a key site of direct hexarelin action in male reproductive biology research. Primary Leydig cells isolated from adult rat testes (collagenase digestion of tunica albuginea-denuded testes, Percoll 30/55/70% step gradient, purified population ≥85% 3β-HSD positive by enzyme histochemistry) express GHSR-1a confirmed by RT-PCR (intron-spanning primers) and immunofluorescence (anti-GHSR-1a antibody, Abcam ab85985). Hexarelin treatment of primary Leydig cells (1-100 nM, 3-24h) activates GHSR-1a-Gq-PLCβ-IP₃-Ca²⁺/DAG-PKC signalling, assessed by Fura-2 AM intracellular Ca²⁺ ratiometric imaging (340/380 nm excitation, Nikon TiE epifluorescence) and DAG assay (Diacylglycerol Kinase Assay, Sigma).

Testosterone biosynthesis endpoints in hexarelin-treated Leydig cell cultures: (i) basal testosterone secretion by RIA or LC-MS/MS in conditioned media at 3, 6, 24h; (ii) LH-stimulated testosterone output (hCG 1 IU/mL positive control) ± hexarelin pre-treatment to assess potentiation; (iii) StAR (steroidogenic acute regulatory protein) protein expression by Western (anti-StAR, Abcam ab58984, 37 kDa band) — the rate-limiting mitochondrial cholesterol import step; (iv) CYP11A1 (cholesterol side-chain cleavage), CYP17A1 (17α-hydroxylase/17,20-lyase), and HSD17B3 (17β-hydroxysteroid dehydrogenase type 3) mRNA by qPCR (Taqman) quantifying the full steroidogenic enzyme cascade. Arachidonic acid release assay (prelabelling with [³H]-arachidonic acid) and ER stress markers (GRP78, ATF4, CHOP) complete the mechanistic panel for hexarelin’s steroidogenic regulation.

Ovarian Research: Granulosa Cell GHSR-1a, Folliculogenesis, and Steroidogenesis

In female reproductive biology research, ovarian granulosa cells are the primary GHSR-1a-expressing cell type relevant to hexarelin effects on folliculogenesis and steroid hormone production. Primary granulosa cells are isolated from gonadotrophin-primed immature rats (PMSG 10 IU i.p., 48h, Sprague-Dawley 21-day females) by follicular aspiration of antral follicles in MEM with 25 mM HEPES, filtered through 40 μm cell strainer, plated at 10⁵ cells/cm² in MEM + 1% FBS + insulin/transferrin/selenium. GHSR-1a expression is confirmed before each experiment by RT-PCR and Western to account for passage-dependent receptor downregulation.

Granulosa cell steroidogenesis research with hexarelin: estradiol (E2) production (ELISA, DRG EIA-2693 or Calbiotech ES168S) in FSH-stimulated cultures ± hexarelin (0.1-100 nM, 24-48h); progesterone (P4) production by RIA in LH/hCG-stimulated cultures; aromatase (CYP19A1) mRNA qPCR and activity assay ([¹,2-³H]-androstenedione → [³H]-water release, aromatase activity nmol/h/mg protein); FSHR expression (RT-PCR, western) tracking follicular maturation state during hexarelin treatment. CYP11A1 and StAR expression in granulosa cells undergoing luteinisation (LH surge simulation with hCG 10 IU/mL) ± hexarelin assesses hexarelin’s role in the LH surge response and corpus luteum formation. Ki-67 immunofluorescence and BrdU incorporation confirm granulosa cell proliferative effects (FSH is the primary mitogen; hexarelin potentiation is assessed relative to FSH dose-response).

GH-IGF-1 Axis and Gonadal Steroidogenesis: Synergistic Mechanisms

Hexarelin’s pro-GH effects create an indirect reproductive biology dimension through the GH-IGF-1 axis. IGF-1 receptors (IGF-1R) are abundantly expressed in both Leydig cells and granulosa cells, and IGF-1 acts synergistically with gonadotrophins (LH in Leydig cells, FSH in granulosa cells) to potentiate steroidogenesis. Research dissecting GH-IGF-1 axis contributions to hexarelin’s reproductive effects employs: (i) GH receptor antagonist pegvisomant (selective GHSR blocker for the GH-dependent arm); (ii) IGF-1 neutralising antibody (R&D AF-291-NA); (iii) phosphatase inhibition of IGF-1R → IRS-1 → PI3K-Akt pathway with LY294002 or Wortmannin at gonadal cell level; and (iv) hypophysectomised (Hx) animal models where hexarelin’s direct gonadal GHSR-1a effects can be assessed without pituitary GH secretion confounding.

In Hx rats supplemented with physiological GH (0.1 mg/kg/day s.c. to restore GH without hexarelin stimulation), hexarelin treatment produces residual effects on testicular weight, plasma testosterone, and Leydig cell StAR expression attributable to direct GHSR-1a action. This GH-independent component is further confirmed using [D-Lys³]-GHRP-6 (GHSR-1a antagonist, 20 μg/kg i.p.) in intact animals: full GHSR blockade eliminates hexarelin’s effect on pulsatile GH but only partially attenuates gonadal steroidogenic responses, consistent with non-GHSR-1a mediated mechanisms (CD36, direct membrane effects) contributing to reproductive tissue responses.

Male Fertility Research Models: Sperm Parameters and Testicular Histology

Translational male fertility research with hexarelin employs both adult healthy and hypogonadal rodent models. In adult male Sprague-Dawley rats (250-300g, treatment 4-8 weeks s.c. hexarelin 100-500 μg/kg/day), sperm parameter assessment: (i) sperm concentration (Neubauer haemocytometer, vas deferens and epididymis cauda flush in BWW medium); (ii) total progressive motility and rapid progressive motility (WHO criteria, CASA — SCA or Hamilton-Thorne IVOS II automated analysis); (iii) morphology (Diff-Quik staining, ≥200 sperm counted, normal vs head/midpiece/tail defects %); (iv) sperm DNA fragmentation index (DFI) by sperm chromatin structure assay (SCSA) or TUNEL flow cytometry (≤15% DFI threshold). Testicular histology (4% PFA, paraffin, H&E 5 μm): Johnsen scoring (1-10) for spermatogenic stages, seminiferous tubule diameter, Leydig cell volume fraction (point counting stereology), and Sertoli cell ratio (number/tubule cross-section).

Hypogonadal research models using hexarelin: (i) chronic restraint stress (CRS, 6h/day × 21 days) inducing functional hypogonadotrophic hypogonadism with reduced LH pulse frequency and testosterone — hexarelin rescue addressing the GH-axis component of stress-induced reproductive suppression; (ii) streptozotocin (STZ, 55 mg/kg i.p.) diabetic model — T1DM-induced testicular dysfunction with oxidative stress (MDA-TBARS, GSH, catalase, SOD in testicular homogenate), Leydig cell apoptosis (TUNEL, caspase-3 IHC), and impaired steroidogenesis correctable by hexarelin’s anti-oxidative GHSR-1a signalling via NRF2-HO-1-NQO1 pathway; (iii) alcohol-induced (ethanol 20% v/v drinking water, 8 weeks) testicular dysfunction with similar oxidative and apoptotic endpoints.

Female Fertility Models: Polycystic Ovary Research and Ovarian Reserve

The polycystic ovary syndrome (PCOS) research model most commonly employed is the letrozole (aromatase inhibitor) or DHT (dihydrotestosterone) implant model in female rats. Letrozole (1 mg/kg/day gavage, 21 days) produces PCOS-like features: elevated LH:FSH ratio, increased testosterone, polycystic ovarian morphology (≥12 antral follicles/ovary on ultrasound or histology, follicular cyst diameter ≥0.25 mm on H&E), anovulation (vaginal smear cytology — persistent cornified/diestrus), and metabolic features (IR-HOMA, OGTT). Hexarelin treatment in letrozole-PCOS rats assesses HPG axis restoration, steroidogenic enzyme normalisation, and follicular development rescue — with the GH-IGF-1 axis intersection relevant to PCOS since GH resistance and IGF-1 excess characterise the PCOS ovarian microenvironment.

Ovarian reserve research uses anti-Müllerian hormone (AMH) as the primary biomarker: serum AMH ELISA (Ansh Labs, ng/mL) reflecting primordial and pre-antral follicle pool. Primordial follicle counting by unbiased stereology (optical fractionator, StereoInvestigator) in serially sectioned ovaries (10 μm, H&E) provides the gold-standard ovarian reserve endpoint. Aged female mice (10-12 months) undergoing hexarelin treatment (chronic 4-8 week s.c.) with comparison to young (3-4 month) controls, measuring AMH, antral follicle count (AFC, vaginal ultrasound or H&E histological count), and estrous cycle regularity (vaginal cytology daily), address the intersection of GH secretagogue biology and reproductive ageing.

Placental and Uterine GHSR-1a Expression: Implantation Research

GHSR-1a expression in human trophoblast cells (HTR-8/SVneo, JEG-3, BeWo) and primary first-trimester cytotrophoblasts (isolated by Percoll gradient from chorionic villi) enables investigation of hexarelin/ghrelin signalling in early placentation. Research endpoints include: trophoblast invasion (Matrigel-coated Boyden 8 μm insert, 48h, DAPI-stained invading cells on underside, fluorescence quantification); trophoblast migration (wound scratch, IncuCyte S3 automated 2h-interval imaging); matrix metalloproteinase secretion (MMP-2, MMP-9 zymography and ELISA, Luminex); and hCG production (β-hCG ELISA in conditioned media, DRG diagnostics) as a trophoblast functional differentiation marker.

Uterine receptivity research with hexarelin focuses on endometrial gland development and implantation window signalling. HOXA10 and HOXA11 (transcription factors critical for uterine receptivity, window day 4 of pseudopregnancy in mice) expression by immunohistochemistry and qPCR in uteri from hexarelin-treated ovariectomised E2/P4-primed mice addresses the role of GHSR-1a signalling in endometrial preparation. Pinopode density (transmission electron microscopy, day 4 pseudopregnancy) and LIF (leukaemia inhibitory factor, ELISA), HOXA10, and integrin αvβ3 expression mark the implantation window — all potentially modulated by hexarelin’s GH/IGF-1 axis effects on uterine biology.

CD36 Receptor: Non-GHSR Mechanism in Reproductive Tissues

Hexarelin’s high-affinity binding to CD36 (a scavenger receptor/fatty acid translocase expressed on macrophages, adipocytes, endothelium, and steroidogenic cells) represents a mechanistically distinct pathway from GHSR-1a activation. CD36 is expressed in ovarian corpus luteum, testicular Leydig cells, and placental trophoblasts, where it mediates cholesterol uptake (essential steroidogenesis substrate) and fatty acid transport. Research using [¹²⁵I]-hexarelin radioligand binding in GHSR-1a-null cell systems (confirming CD36 as the binding partner) and CD36-selective antagonist SSO (sulfo-N-succinimidyl oleate, 10 μM) dissects GHSR-1a-independent hexarelin effects in steroidogenic cells. CD36-mediated cholesterol uptake enhancement (BODIPY-cholesterol fluorescent tracer, flow cytometry) and StAR-independent mitochondrial cholesterol import in hexarelin-treated Leydig cells provide mechanistic readouts for the non-canonical reproductive biology pathway.

Control Design for Reproductive Biology Research

Rigorous hexarelin reproductive research requires: (i) oestrous cycle staging — all female experiments timed to defined cycle stage (proestrus, estrus, metestrus, diestrus) by vaginal cytology, as hormonal responsiveness varies dramatically across the cycle; (ii) GHSR-1a specificity controls — [D-Lys³]-GHRP-6 (GHSR-1a antagonist) and CD36 antagonist SSO administered separately and in combination to fully attribute effects to each receptor; (iii) GH-axis dissection — Hx model or GH receptor antagonist pegvisomant for GH-independent gonadal GHSR-1a effects; (iv) gonadotrophin controls — hCG (LH surrogate, 1-10 IU/mL in vitro or 10 IU i.p. in vivo) as maximal steroidogenic stimulation positive control; (v) sex hormone ELISAs — validated assay kits with species-appropriate cross-reactivity (rodent vs human); (vi) diurnal timing — hexarelin GH release is circadian (pulsatile in rodents with highest amplitude during early dark phase), requiring fixed-time dosing and sampling protocols; (vii) peptide purity — ≥98% HPLC, mass confirmation by LC-MS/MS, endotoxin ≤1 EU/mg (endotoxin can directly stimulate gonadal steroidogenesis via TLR4, confounding results).